However, within 24 h of administration to mice bearing HER2-positive tumours, 111In-(HE)3-G3 DARPin achieved higher tumour-to-blood ratios than other reported HER2 radioligands, including whole antibodies, Fab fragments of antibodies and small high-affinity proteins [28–31]. Here, ERBB2 is linked to neoplasm.